Caeregen Therapeutics is focused on discovering and developing novel drug therapies which repair, restore, and protect damaged and diseased tissues by reactivating the pathways and signaling which accompanies normal cellular and tissue development
December 8, 1946 – October 21, 2022. Dr. Trese was a great and inspirational leader, friend, and colleague whose warmth, wit, and generosity of spirit knew no boundaries.
PhD in Molecular Genetics and Microbiology (UF)− Director of Pediatric Retinal Disease Molecular Genetics Laboratory at Oakland University Eye Research Institute.
Associated Retinal Consultants, Royal Oak, MI−President, Pediatric Retinal Research Foundation−Extensive clinical trial experience.
Extensive innovations in intravitreal, gene and surgical adjuvant drug therapy. Founding Director of the Byers Eye Institute at Stanford.
Deep drug development back-ground, having ushered >25 drugs from various phases of development to commercial/clinical use−Former CEO/President, Multiple Myeloma Research Foundation.
Over 30 years conducting eye research. Spanning basic, translational and product development.
Expert in age-related macular degeneration Vice Chair for Research and founder of the Center for Advanced Vision Science, University of Virginia
Expert in diabetic retinopathy Director of Beetham Eye Institute at Joslin Diabetes Center, Harvard Medical School
Extensive innovations in intravitreal, gene and surgical adjuvant drug therapy. Founding Director of the Byers Eye Institute at Stanford.
Discovered vascular endothelial growth factor (VEGF), Senior Deputy Director, Basic Science at UC San Diego
Expert in retinopathy of prematurity and vascular growth mechanisms. Professor of Ophthalmology, Harvard Medical School
Learn more about investing in our innovation.
Rochester, MI, USA, July 17, 2023 – Caeregen Therapeutics announced today that it has been awarded a $1.4 million Phase 2 Small Business Innovation Research (SBIR) grant from the National Institutes o...
Rochester, MI, USA and Halle, Germany, June 28, 2023 – Caeregen Therapeutics, a regenerative medicine therapeutics company and Wacker Biotech, a contract development and manufacturing organization (CD...
It is with great sadness we announce the passing of Dr. Michael T. Trese, co-founder and Chief Technology Officer of Caeregen Therapeutics. Dr. Trese was one of the pioneers, leading innovators, and ...